Pyramax®

Shin Poong

Product category
  • 3-day cure, artemisinin-based combination therapy (pyronaridine-artesunate)

Therapeutic indication
  • Pyramax tablets: Treatment of uncomplicated malaria caused by P. falciparum or by P. vivax in adults and children ≥20kg

Dosing
  • Once-daily for 3 days

Efficacy
  • 28-day PCR-corrected ACPR* >98%

  • 42-day PCR-corrected ACPR* 90%–95%

Key features
  • Only ACT approved by a stringent regulatory authority for both P. falciparum and P. vivax (blood-stage)
  • No food restrictions
Challenges
  • WHO Information Note of October 2019 now supports use, yet not formally included in WHO Malaria Treatment Guidelines

Status
  • Positive opinion from EMA (Article 58); new label (tablets) in 2015. Cross-listed on WHO list of prequalified medicines. Included in WHO Essential Medicines List (adults and children) and use now supported by WHO Information Note

  • Included in national treatment guidelines of Benin, Cameroon, Côte d’Ivoire, Niger and Republic of Congo

  • Approved in 26 countries, country launches began in 2018 in sub-Saharan Africa

Next milestone
  • Completion of multi-country phase IIIb/IV CANTAM study for publication
  • Continued commercial introduction in Africa
Previously
  • Development project team led by University of Iowa

MMV Project Director
  • Adam Aspinall

* ACPR = adequate clinical and parasitological response